Trial intelligence / Profile preview

Exparel vs Bupivacaine in TAP Block for Gynecologic Surgery

NCT03304444Phase 3

Key facts

Status: Unknown
Start: Aug 2016
Primary completion: Oct 2017
Countries: 1
Sponsor: Jefferson Abington Hospital
Modality: Small Molecules

Drugs: bupivacaine
Conditions: postoperative pain

Overview

Phase 3, randomised trial of bupivacaine in postoperative pain (2 arms), sponsored by Jefferson Abington Hospital. Primary endpoint: Length of stay post operatively in hospital. Status: unknown.

Design

2 arms

Study design: Randomized

Bupivacaine HCl
TAP block with Bupivacaine HCl
Exparel + Bupivacaine
TAP block with Exparel diluted with Bupivacaine HCl

Who it enrols

Adult female patients undergoing planned exploratory laparotomy for gynecologic surgery. Excludes pregnant patients, minimally invasive surgeries, and those with severe hepatic or renal disease.

Endpoints

Primary

Length of stay post operatively in hospitalthrough study completion

Secondary

total opioid use post operatively in hospitalthrough study completion
overall complications ratesthrough study completion

Beyond the preview

Go deeper on NCT03304444.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03304444.